trending Market Intelligence /marketintelligence/en/news-insights/trending/qP6ehNnZl_Gh8Gy-QvWHhQ2 content esgSubNav
In This List

US FDA accepts VBI Vaccines application for brain tumor drug

Blog

Insight Weekly: Private equity slows; SPAC underwriters retreat; carbon capture boost

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms


US FDA accepts VBI Vaccines application for brain tumor drug

The U.S. Food and Drug Administration accepted VBI Vaccines Inc.'s investigational new drug application for VBI-1901, an immunotherapy to treat glioblastoma multiforme.

Glioblastoma multiforme is the most common and aggressive malignant primary brain tumors in humans.

VBI Vaccines intends to evaluate the drug in the second half of 2017 in a phase 1/2a clinical trial in patients with recurrent glioblastoma multiforme.